Next Article in Journal
Multiparameter Flow Cytometry to Detect Hematogones and to Assess B-Lymphocyte Clonality in Bone Marrow Samples from Patients with Non-Hodgkin Lymphomas
Previous Article in Journal
Hemophagocytic Lymphohistiocytosis and Pelger-Huët Anomaly Associated with Colchicine Intoxication
 
 
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Intensive Serial Biomarker Profiling for the Prediction of Neutropenic Fever in Patients with Hematologic Malignancies Undergoing Chemotherapy: A Pilot Study

1
Division of Hematology, Department of Medicine, Stanford University School of Medicine/Stanford Cancer Institute, 875 Blake Wilbur Drive, Room 2324, Stanford, CA 94305-5821, USA
2
North Western Deanery, Three Piccadilly Place, Manchester, UK
3
Theranos Inc., Palo Alto, CA, USA
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2014, 6(2), 5466; https://doi.org/10.4081/hr.2014.5466
Submission received: 26 April 2014 / Revised: 5 June 2014 / Accepted: 9 June 2014 / Published: 23 June 2014

Abstract

Neutropenic fever (NF) is a life-threatening complication of myelosuppressive chemotherapy in patients with hematologic malignancies and triggers the administration of broad-spectrum antimicrobials. The ability to accurately predict NF would permit initiation of antimicrobials earlier in the course of infection with the goal of decreasing morbid complications and progression to septic shock and death. Changes in the blood level of inflammatory biomarkers may precede the occurrence of NF. To identify potential biomarkers for the prediction of NF, we performed serial meas- urements of nine biomarkers [C-reactive protein (CRP), protein C, interleukin (IL)-6, IL-8, IL-10, IL-1β, tumor necrosis factor-α, monocyte chemotactic protein-1, and intercellular adhesion molecule-1] using a multiplex ELISA array platform every 6-8 hours in patients undergoing myelosuppressive chemotherapy for hematologic malignancies. We found that the blood levels of IL-6 and CRP increased significantly 24 to 48 hours prior to the onset of fever. In addition, we showed that frequent biomarker monitoring is feasible using a bedside micro sample test device. The results of this pilot study suggest that serial monitoring of IL-6 and CRP levels using a bedside device may be useful in the prediction of NF. Prospective studies involving a larger cohort of patients to validate this observation are warranted. This trial is registered at ClinicalTrials.gov (NCT01144793).
Keywords: neutropenic fever; interleukin-6; C-reactive protein; acute leukemia neutropenic fever; interleukin-6; C-reactive protein; acute leukemia

Share and Cite

MDPI and ACS Style

Chan, S.M.; Chadwick, J.; Young, D.L.; Holmes, E.; Gotlib, J. Intensive Serial Biomarker Profiling for the Prediction of Neutropenic Fever in Patients with Hematologic Malignancies Undergoing Chemotherapy: A Pilot Study. Hematol. Rep. 2014, 6, 5466. https://doi.org/10.4081/hr.2014.5466

AMA Style

Chan SM, Chadwick J, Young DL, Holmes E, Gotlib J. Intensive Serial Biomarker Profiling for the Prediction of Neutropenic Fever in Patients with Hematologic Malignancies Undergoing Chemotherapy: A Pilot Study. Hematology Reports. 2014; 6(2):5466. https://doi.org/10.4081/hr.2014.5466

Chicago/Turabian Style

Chan, Steven M., John Chadwick, Daniel L. Young, Elizabeth Holmes, and Jason Gotlib. 2014. "Intensive Serial Biomarker Profiling for the Prediction of Neutropenic Fever in Patients with Hematologic Malignancies Undergoing Chemotherapy: A Pilot Study" Hematology Reports 6, no. 2: 5466. https://doi.org/10.4081/hr.2014.5466

Article Metrics

Back to TopTop